Ubs Oconnor LLC Axsome Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

$1.59 Billion
Q1 2024

A detailed history of Ubs Oconnor LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 8,918 shares of AXSM stock, worth $703,897. This represents 0.04% of its overall portfolio holdings.

Number of Shares

8,918

Holding current value

$703,897

% of portfolio

0.04%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $208,447 - $293,310	-3,004 Reduced 25.2%	8,918 $711,000
Q4 2023 Feb 14, 2024	SELL	$57.42 - $83.61 $793,142 - $1.15 Million	-13,813 Reduced 53.67%	11,922 $948,000
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $1.5 Million - $2.33 Million	25,735 New	25,735 $1.85 Billion
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $705,059 - $905,625	12,075 Added 115.1%	22,566 $1.39 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $219,310 - $437,742	5,491 Added 109.82%	10,491 $0

Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $830,317 - $1.61 Million	-23,026 Reduced 82.16%	5,000 $223 Million
Q2 2022 Aug 12, 2022	BUY	$21.74 - $46.75 $133,179 - $286,390	6,126 Added 27.97%	28,026 $1.07 Million
Q1 2022 May 16, 2022	BUY	$23.7 - $41.39 $519,030 - $906,441	21,900 New	21,900 $906,000

Others Institutions Holding AXSM

# of Institutions

290

Shares Held

37.1M

Call Options Held

401K

Put Options Held

464K

Rtw Investments, LP New York, NY

4.49M
Shares

$355 Million
5.75% of portfolio
Vanguard Group Inc Valley Forge, PA

3.74M
Shares

$295 Million
0.01% of portfolio
Black Rock Inc. New York, NY

3.2M
Shares

$252 Million
0.01% of portfolio
Fairmount Funds Management LLC Philadelphia, PA

2.36M
Shares

$186 Million
30.01% of portfolio
Deep Track Capital, LP Greenwich, CT

1.3M
Shares

$103 Million
3.44% of portfolio

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account